TRIANA Biomedicines
Rationally designed molecular glue degrader therapeutics targeting protein-protein interactions
- Sector
- Biotech
- Headquarters
- LEXINGTON, MA
- Founded
- 2019
- Latest Form D
- $120M, Dec 2025
- Total capital
- $171M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $171M
- 4 Form D · last Dec 2025
- 11 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 39 pending · first 2026
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$120M
- Private capital raisedForm D · SEC · 3rd filing$34.8M
- Private capital raisedForm D · SEC · 2nd filing$10M
- Private capital raisedForm D · SEC · 1st filing$6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew HedinDirectorNamed in SEC Form D filings
- Christopher O'DonnellDirectorNamed in SEC Form D filings
- David GrayzelDirectorNamed in SEC Form D filings
- Jigar RaythathaDirectorNamed in SEC Form D filings
- Joshua ResnickDirectorNamed in SEC Form D filings
- Lorence KimDirectorNamed in SEC Form D filings
Show all 10 people
- Milind DeshpandeDirectorNamed in SEC Form D filings
- Patrick TrojerExecutive Officer, DirectorNamed in SEC Form D filings
- Shelley ChuDirectorNamed in SEC Form D filings
- Simon ReadDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 40- GrantedAnaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofUSPTOUS 12,565,492
- PendingFused Bicyclic Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofUSPTOApplication 18699461
- PendingAmide And Ether Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofUSPTOApplication 18276433
Show all 40 patent records
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofMar 3, 2026 · US 12,565,492Granted
- Fused Bicyclic Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofDec 26, 2024 · Application 18699461Pending
- Amide And Ether Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofOct 3, 2024 · Application 18276433Pending
- Sulfonamide Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofJun 13, 2024 · Application 18275382Pending
- Systems And Methods To Predict Protein-protein InteractionMay 2, 2024 · Application 18376729Pending
- Modulators Of CDK2 And Uses ThereofApplication PCTUS2025032905Pending
- Molecular Glues And Uses ThereofApplication PCTUS2025016564Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63757500Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63747667Pending
- Modulators Of CDK2 And Uses ThereofApplication 63726701Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63723238Pending
- Targeted Protein DegradationApplication PCTUS2024052569Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63710416Pending
- Molecular Glues And Uses ThereofApplication 63706906Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63681228Pending
- Anaplastic Lymphoma Kinase Degraders And Methods Of UseApplication 63681226Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63681229Pending
- Systems And Methods For Predicting Protein-protein Interactions Using Machine Learning TechniquesApplication 63669129Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63668355Pending
- Modulators Of CDK2 And Uses ThereofApplication 63658487Pending
- Modulators Of CDK2 And Uses ThereofApplication PCTUS2024033263Pending
- Molecular Glues And Uses ThereofApplication 63555527Pending
- Targeted Protein DegradationApplication 63545875Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication PCTUS2026015025Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication PCTUS2026010684Pending
- Modulators Of CDK2 And Uses ThereofApplication 19492496Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63900193Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63812435Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63758236Pending
- Anaplastic Lymphoma Kinase (alk) Degraders And Uses ThereofApplication 63743459Pending
- Systems And Methods To Predict Protein-protein InteractionApplication PCTUS2023034457Pending
- Modulators Of CDK2 And Uses ThereofApplication 63472407Pending
- Methods And Systems To Predict Protein-protein InteractionApplication 63414233Pending
- Fused Bicyclic Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofApplication PCTUS2022046088Pending
- Amide And Ether Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofApplication PCTUS2022015786Pending
- Sulfonamide Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofApplication PCTUS2022014723Pending
- Fused Bicyclic Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofApplication 63254007Pending
- Amide And Ether Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofApplication 63147430Pending
- Sulfonamide Substituted N-(1H-INDOL-7-YL)BENZENESULFONAMIDES And Uses ThereofApplication 63144580Pending
- Targeted Protein DegradationApplication 19581832Pending
Related companies, and why
- BIOHARVEST SCIENCES INC.Similar federal contract value in Biotech · null in contracts
- Celcuity Inc.Similar federal contract value in Biotech · null in contracts
- Areteia TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Monocacy Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Fulcrum TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Erasca, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .